Tag: HRS 2025
HeartBeam’s synthesised 12-lead ECG meets clinical endpoints in VALID-ECG study
HeartBeam has announced that its “groundbreaking” synthesised 12-lead electrocardiogram (ECG) successfully met the clinical endpoints in the VALID-ECG pivotal study. Thomas Deering (Piedmont Heart...
Multicentre study suggests GLP-1 receptor agonists may reduce AF-related events in...
The TRANSFORM-AF study has found that patients with atrial fibrillation (AF) and obesity who were treated with a glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
Circa Scientific announces US FDA clearance of PeriCross epicardial access kit
Circa Scientific has announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the PeriCross epicardial access kit (formerly Rook),...
Research unveiled at HRS 2025 highlights AI’s ability to enhance cardiac...
New research unveiled at the 2025 Heart Rhythm Society (HRS) annual meeting (24–27 April, San Diego, USA) has underscored the critical role of artificial...
Abbott, Medtronic announce positive data on respective PFA systems at HRS...
Among a great number of presentations relating to pulsed field ablation (PFA) treatments for atrial fibrillation (AF) at this year’s Heart Rhythm Society (HRS)...
Kardium announces “impressive” one-year PULSAR IDE study results with Globe PF system
Kardium has announced late-breaking, one-year clinical trial results with its innovative pulsed field ablation (PFA) device—the Globe PF system.
Pivotal findings from the PULSAR...
Field Medical announces promising first-in-human data on treating scar-related VT using...
Field Medical has announced that its FieldForce ablation system was recently featured in a scientific presentation at the 2025 Heart Rhythm Society (HRS) annual...
Abbott highlights new Aveir data and initiates CSP technology trial
Abbott has announced late-breaking data from the AVEIR conduction system pacing (CSP) acute clinical feasibility study, demonstrating the safety and performance of the company’s investigational...
Medtronic receives US FDA approval for OmniaSecure lead and announces investigational...
Medtronic has received US Food and Drug Administration (FDA) approval of the OmniaSecure defibrillation lead for placement within the right ventricle. The lead—based on...
Atraverse presents clinical data on Hotwire transseptal access system at HRS...
Atraverse Medical has announced that the latest clinical evidence on the efficacy and safety of its Hotwire left heart access system were presented at...
Second phase of Boston’s ADVANTAGE AF study meets primary safety and...
Boston Scientific has announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the...
J&J MedTech presents new Omny-IRE and VARIPURE study data at HRS...
Johnson & Johnson (J&J) MedTech has announced positive initial three-month results from the Omny-IRE study evaluating the investigational Omnypulse platform in patients with paroxysmal...
Stereotaxis features first-ever live demonstration of GenesisX robotic system at HRS...
Stereotaxis announced recently that it hosted a demonstration of the GenesisX robotic system at this year’s Heart Rhythm Society (HRS) meeting (24–27 April, San...